Longidaza suppositories 3000 IU 10 pcs
Condition: New product
969 Items
Rating:
Be the first to write a review!
More info
Description
Torpedo-shaped suppositories, light yellow in color with a slight specific smell of cocoa butter, marbling staining is allowed.
Active ingredients
Hyaluronidase + Azoxymere Bromide
Release form
Suppositories
Composition
Active ingredient: Bovgialuronidazozoksimer (Longidaza®) - 3000 IU
Auxiliary substance: cocoa butter - to obtain a suppository weighing 1.3 g
Auxiliary substance: cocoa butter - to obtain a suppository weighing 1.3 g
Pharmacological effect
Longidaza® has hyaluronidase (enzymatic) activity of prolonged action, chelating, antioxidant, immunomodulatory and moderately pronounced anti-inflammatory properties.
The prolongation of the enzyme action is achieved by covalent binding of the enzyme with a physiologically active polymeric carrier (azoxymer). Longidase® shows anti-fibrotic properties, weakens the acute phase of inflammation, regulates (increases or decreases depending on the initial level) synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor - alpha), increases the humoral immune response and resistance of the organism to infection.
Pronounced anti-fibrotic properties of Longidaza are provided by conjugation of hyaluronidase with a carrier, which significantly increases the resistance of the enzyme to denaturing effects and to the action of inhibitors: Longididase enzymatic activity is maintained when heated to 37 ° C for 20 days, while native hyaluronidase loses its activity under the same conditions during the day. In the preparation of Longidaza, the simultaneous local presence of the enzyme hyaluronidase and a carrier is provided that is capable of binding enzyme inhibitors and stimulants of collagen synthesis (iron, copper, heparin, etc.) released during the hydrolysis of the matrix components. Due to these properties, Longidase® not only has the ability to depolymerize the matrix of connective tissue in fibrous granulomatous masses, but also to suppress the reverse regulatory response, aimed at the synthesis of components of connective tissue.
The specific substrate of testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix.As a result of depolymerization (breaking the bond between C1 acetylglucosamine and C4 glucuronic or induronic acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water decreases, metal ions temporarily increase the permeability of tissue barriers, fluid flow in the intercellular space increases, elasticity of connective tissue increases , which is manifested in a decrease in tissue swelling, flattening of scars, an increase in the volume of movement of the joints, a decrease in contractures and ezhdenii their formation, reduction of adhesions. Biochemical, immunological, histological and electron microscopic studies have shown that Longidase® does not damage normal connective tissue, but causes destruction of the composition and structure of the connective tissue in the area of fibrosis.
Longidase® does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.
The drug is well tolerated by patients, there are no local and general allergic reactions.
The use of Longidaza in therapeutic doses during or after surgical treatment does not cause deterioration of the postoperative period or progression of the infectious process, does not slow down the recovery of bone tissue.
The prolongation of the enzyme action is achieved by covalent binding of the enzyme with a physiologically active polymeric carrier (azoxymer). Longidase® shows anti-fibrotic properties, weakens the acute phase of inflammation, regulates (increases or decreases depending on the initial level) synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor - alpha), increases the humoral immune response and resistance of the organism to infection.
Pronounced anti-fibrotic properties of Longidaza are provided by conjugation of hyaluronidase with a carrier, which significantly increases the resistance of the enzyme to denaturing effects and to the action of inhibitors: Longididase enzymatic activity is maintained when heated to 37 ° C for 20 days, while native hyaluronidase loses its activity under the same conditions during the day. In the preparation of Longidaza, the simultaneous local presence of the enzyme hyaluronidase and a carrier is provided that is capable of binding enzyme inhibitors and stimulants of collagen synthesis (iron, copper, heparin, etc.) released during the hydrolysis of the matrix components. Due to these properties, Longidase® not only has the ability to depolymerize the matrix of connective tissue in fibrous granulomatous masses, but also to suppress the reverse regulatory response, aimed at the synthesis of components of connective tissue.
The specific substrate of testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix.As a result of depolymerization (breaking the bond between C1 acetylglucosamine and C4 glucuronic or induronic acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water decreases, metal ions temporarily increase the permeability of tissue barriers, fluid flow in the intercellular space increases, elasticity of connective tissue increases , which is manifested in a decrease in tissue swelling, flattening of scars, an increase in the volume of movement of the joints, a decrease in contractures and ezhdenii their formation, reduction of adhesions. Biochemical, immunological, histological and electron microscopic studies have shown that Longidase® does not damage normal connective tissue, but causes destruction of the composition and structure of the connective tissue in the area of fibrosis.
Longidase® does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.
The drug is well tolerated by patients, there are no local and general allergic reactions.
The use of Longidaza in therapeutic doses during or after surgical treatment does not cause deterioration of the postoperative period or progression of the infectious process, does not slow down the recovery of bone tissue.
Pharmacokinetics
An experimental study of pharmacokinetics allowed to establish that when administered rectally, the drug Longidase® is characterized by a high rate of distribution in the body, is well absorbed into the systemic circulation and reaches its maximum concentration in the blood after 1 hour. The half-distribution period is about 0.5 hours, the half-elimination period is from 42 to 84 hours. Excreted mainly by the kidneys.
The drug penetrates into all organs and tissues, including passes through the blood-brain and blood-brain barriers. Established the absence of tissue cumulation.
The bioavailability of the drug Longidase® with rectal administration is high: about 90%.
The drug penetrates into all organs and tissues, including passes through the blood-brain and blood-brain barriers. Established the absence of tissue cumulation.
The bioavailability of the drug Longidase® with rectal administration is high: about 90%.
Indications
Adults and adolescents over 12 years of age as monotherapy and as part of a complex therapy of diseases involving connective tissue hyperplasia, including against the background of the inflammatory process:
• in urology: chronic prostatitis, interstitial cystitis, strictures of the urethra and ureters, Peyronie's disease, the initial stage of benign prostatic hyperplasia, prevention of scar formation and stricture after surgical interventions on the urethra, bladder, ureters,
• in gynecology: adhesions (prevention and treatment) in the small pelvis for chronic inflammatory diseases of the internal genital organs, after gynecological manipulations, including artificial abortions, previous surgical interventions on the pelvic organs, intrauterine synechiae, tubo-peritoneal infertility, chronic endomyometritis,
• in dermatovenereology: limited scleroderma, prevention of fibrous complications of sexually transmitted infections,
• in surgery: prevention and treatment of adhesions after surgery on the abdominal organs, nonhealing wounds,
• in pulmonology and phthisiology: pneumofibrosis, siderosis, tuberculosis (cavernous-fibrous, infiltrative, tuberculoma), interstitial pneumonia, fibrosing alveolitis, pleurisy,
• to increase the bioavailability of antibiotic therapy in urology, gynecology, dermatology, surgery, pulmonology, etc.
• in urology: chronic prostatitis, interstitial cystitis, strictures of the urethra and ureters, Peyronie's disease, the initial stage of benign prostatic hyperplasia, prevention of scar formation and stricture after surgical interventions on the urethra, bladder, ureters,
• in gynecology: adhesions (prevention and treatment) in the small pelvis for chronic inflammatory diseases of the internal genital organs, after gynecological manipulations, including artificial abortions, previous surgical interventions on the pelvic organs, intrauterine synechiae, tubo-peritoneal infertility, chronic endomyometritis,
• in dermatovenereology: limited scleroderma, prevention of fibrous complications of sexually transmitted infections,
• in surgery: prevention and treatment of adhesions after surgery on the abdominal organs, nonhealing wounds,
• in pulmonology and phthisiology: pneumofibrosis, siderosis, tuberculosis (cavernous-fibrous, infiltrative, tuberculoma), interstitial pneumonia, fibrosing alveolitis, pleurisy,
• to increase the bioavailability of antibiotic therapy in urology, gynecology, dermatology, surgery, pulmonology, etc.
Contraindications
• hypersensitivity to drugs based on hyaluronidase,
• pulmonary hemorrhage and hemoptysis,
• fresh vitreous hemorrhage,
• malignant neoplasms,
• acute renal failure,
• children's age up to 12 years (results of clinical studies are absent),
• pregnancy and breastfeeding period.
• pulmonary hemorrhage and hemoptysis,
• fresh vitreous hemorrhage,
• malignant neoplasms,
• acute renal failure,
• children's age up to 12 years (results of clinical studies are absent),
• pregnancy and breastfeeding period.
Precautionary measures
With caution, use no more than 1 time per week in patients with chronic renal failure, pulmonary hemorrhages in history.
Use during pregnancy and lactation
Contraindicated use during pregnancy and during breastfeeding (clinical experience with no).
Dosage and administration
Longidase® 3000 IU suppositories are recommended for rectal or vaginal use once a day for a night course of 10 to 20 administrations.
For adolescents from 12 to 18 years old, suppositories are administered only rectally.
Adults and adolescents over 12 years of age rectally: 1 suppository 1 time per day after bowel cleansing.
Adults vaginally: 1 suppository 1 time per day (at night) suppository is inserted into the vagina in the prone position.
The scheme of administration is adjusted depending on the severity, stage and duration of the disease: Longidase® is prescribed every other day or with intervals of 2-3 days.
Recommended regimens and doses:
• in urology: 1 suppository every other day 10 injections, then in 2-3 days
10 injections, a general course of 20 suppositories.
• in gynecology: rectally or vaginally, 1 suppository after 2 days
10 injections, then, if necessary, maintenance therapy is prescribed.
• in dermatology and venereology: 1 suppository in 1–2 days for 10–15 injections.
• in surgery: 1 suppository in 2-3 days, 10 injections.
• in pulmonology and phthisiology: 1 suppository in 2-4 days, 10-20 injections.
If necessary, a repeated course of the drug Longidaza® is recommended not earlier than in three months or long-term supportive therapy for 1 suppository 1 time in 5-7 days for 3-4 months.
For adolescents from 12 to 18 years old, suppositories are administered only rectally.
Adults and adolescents over 12 years of age rectally: 1 suppository 1 time per day after bowel cleansing.
Adults vaginally: 1 suppository 1 time per day (at night) suppository is inserted into the vagina in the prone position.
The scheme of administration is adjusted depending on the severity, stage and duration of the disease: Longidase® is prescribed every other day or with intervals of 2-3 days.
Recommended regimens and doses:
• in urology: 1 suppository every other day 10 injections, then in 2-3 days
10 injections, a general course of 20 suppositories.
• in gynecology: rectally or vaginally, 1 suppository after 2 days
10 injections, then, if necessary, maintenance therapy is prescribed.
• in dermatology and venereology: 1 suppository in 1–2 days for 10–15 injections.
• in surgery: 1 suppository in 2-3 days, 10 injections.
• in pulmonology and phthisiology: 1 suppository in 2-4 days, 10-20 injections.
If necessary, a repeated course of the drug Longidaza® is recommended not earlier than in three months or long-term supportive therapy for 1 suppository 1 time in 5-7 days for 3-4 months.
Side effects
The frequency of adverse reactions is presented according to the following classification:
very frequent ≥ 10%, frequent ≥ 1% and <10%, infrequent ≥ 0.1% and <1%, rare ≥ 0.01%
and <0.1%, very rare <0.001%.
Very rarely: local reactions in the form of redness, swelling, itching of the perianal zone, vaginal itching due to individual sensitivity to the components of the drug.
very frequent ≥ 10%, frequent ≥ 1% and <10%, infrequent ≥ 0.1% and <1%, rare ≥ 0.01%
and <0.1%, very rare <0.001%.
Very rarely: local reactions in the form of redness, swelling, itching of the perianal zone, vaginal itching due to individual sensitivity to the components of the drug.
Overdose
Overdose symptoms can manifest as chills, fever, dizziness, hypotension. Drug administration is stopped and symptomatic therapy is prescribed.
Interaction with other drugs
Longidis® can be combined with antibiotics, antivirals, antifungals, and bronchodilators. When prescribed in combination with other drugs (antibiotics, local anesthetics, diuretics), the possibility of increasing bioavailability and enhancing their action should be considered. When combined with high doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogen, or antihistamine drugs, the enzyme activity of the drug Longidase® can be reduced.
Do not use the drug Longidase® simultaneously with drugs containing furosemide, benzodiazepines, phenytoin.
Do not use the drug Longidase® simultaneously with drugs containing furosemide, benzodiazepines, phenytoin.
special instructions
When taking the drug strictly follow the instructions given in the instructions.
If you have any questions, ask your doctor or pharmacist for clarification.
With the development of an allergic reaction to interrupt the use of the drug Longidase®.
When applied against the background of exacerbation of foci of infection to prevent the spread of infection, it is necessary to prescribe it under the cover of antimicrobial agents.
With the appearance of adverse reactions, as well as with the appearance of an adverse reaction that is not mentioned in the instructions for medical use, you should contact your doctor.
Do not use the drug in the presence of visual signs of its unsuitability (packaging defect, suppository color change).
In case of skipping the introduction of the next dose of the drug, then apply as usual (do not enter a double dose).
If you need to stop taking the drug Longidase®, the cancellation can be done immediately, without gradually reducing the dose.
INFLUENCE ON THE ABILITY TO MANAGE THE VEHICLES, MECHANISMS
The use of the drug Longidase® does not affect the ability to drive vehicles, maintain mechanisms and other types of work that require high concentration of attention and speed of psychomotor reactions.
If you have any questions, ask your doctor or pharmacist for clarification.
With the development of an allergic reaction to interrupt the use of the drug Longidase®.
When applied against the background of exacerbation of foci of infection to prevent the spread of infection, it is necessary to prescribe it under the cover of antimicrobial agents.
With the appearance of adverse reactions, as well as with the appearance of an adverse reaction that is not mentioned in the instructions for medical use, you should contact your doctor.
Do not use the drug in the presence of visual signs of its unsuitability (packaging defect, suppository color change).
In case of skipping the introduction of the next dose of the drug, then apply as usual (do not enter a double dose).
If you need to stop taking the drug Longidase®, the cancellation can be done immediately, without gradually reducing the dose.
INFLUENCE ON THE ABILITY TO MANAGE THE VEHICLES, MECHANISMS
The use of the drug Longidase® does not affect the ability to drive vehicles, maintain mechanisms and other types of work that require high concentration of attention and speed of psychomotor reactions.
Storage conditions
In a dry dark place at a temperature of from 2 to 15 ° C. Keep out of the reach of children.
Shelf life after opening
2 years. Do not use after the expiration date printed on the package.